These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35985203)

  • 1. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
    Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
    Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
    Shi X; Li S; Tang S; Lu Y
    Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3 suppresses anlotinib sensitivity by regulating m
    Chen J; Li S; Huang Z; Cao C; Wang A; He Q
    Cancer Cell Int; 2022 Sep; 22(1):295. PubMed ID: 36167542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo.
    Zhang X; Geng L; Yang L; Wang Y; Zou Z; Zhang Y; Xu H; Lei H; Cao Y; Wu Y; Gu W; Zhou L
    Cell Signal; 2023 Oct; 110():110837. PubMed ID: 37544636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway.
    Wang J; Xu Z; Lai Y; Zhang Y; Zhang P; Mu Q; Yang S; Sheng L; Ouyang G
    Curr Mol Med; 2024 Apr; ():. PubMed ID: 38659267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
    Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
    Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
    Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
    World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe.
    Deng Z; Liao W; Wei W; Zhong G; He C; Zhang H; Liu Q; Xu X; Liang J; Liu Z
    Cancer Cell Int; 2021 Jan; 21(1):37. PubMed ID: 33422069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
    Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
    Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
    Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q
    Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
    Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
    Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K/Akt signaling pathway.
    Liu Y; Li F; Wang Q; Zhang Y; Tian S; Li B
    Discov Oncol; 2024 Apr; 15(1):134. PubMed ID: 38678128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
    Cao Y; Shan H; Liu M; Liu J; Zhang Z; Xu X; Liu Y; Xu H; Lei H; Yu M; Zhang X; Liu W; Bu Z; Fang Z; Ji Y; Yan H; Gu W; Wu Y
    Cell Death Dis; 2021 Apr; 12(4):396. PubMed ID: 33854043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway.
    Xia T; Zhang J; Zhou C; Li Y; Duan W; Zhang B; Wang M; Fang J
    J Ginseng Res; 2020 Sep; 44(5):725-737. PubMed ID: 32913402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
    Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
    Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.